Late-breaking and deferred publication abstractsNSCLC, metastaticLBA51 - Phase 2 trial (BRF113928) of dabrafenib (D) plus trametinib (T) in patients (pts) with previously untreated BRAF V600E–mutant metastatic non-small cell lung cancer (NSCLC)
NSCLC, metastatic
Under an Elsevier user license
open archive
Cited by (0)
Copyright © 2017 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved.